PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Signal transducer and activator of transcription 3 (STAT3) promoter methylation and expression in pituitary adenoma.

Abstract Pituitary adenoma (PA) is a benign brain tumor that can cause neurological, endocrinological and ophthalmological aberrations. Till now there is a need to identify factors that can influence the tumor invasiveness and recurrence. The aim of this study was to evaluate the associations between the signal transducer and activator of transcription 3 (STAT3) promoter methylation, mRNA expression and the invasiveness or recurrence of PAs and patient clinical characteristics.
PMID
Related Publications

Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas.

Expression of cold-inducible RNA-binding protein (CIRP) in pituitary adenoma and its relationships with tumor recurrence.

MicroRNA-124 regulates STAT3 expression and is down-regulated in colon tissues of pediatric patients with ulcerative colitis.

A pilot genome-scale profiling of DNA methylation in sporadic pituitary macroadenomas: association with tumor invasion and histopathological subtype.

N-myc downstream-regulated gene 2 (NDRG2) promoter methylation and expression in pituitary adenoma.

Authors

Mayor MeshTerms

Promoter Regions, Genetic

Keywords

DNA methylation

Invasiveness

Pituitary adenoma

Signal transducer and activator of transcription 3

mRNA expression

Journal Title bmc medical genetics
Publication Year Start




PMID- 28709401
OWN - NLM
STAT- MEDLINE
DA  - 20170715
DCOM- 20170724
LR  - 20170724
IS  - 1471-2350 (Electronic)
IS  - 1471-2350 (Linking)
VI  - 18
IP  - 1
DP  - 2017 Jul 14
TI  - Signal transducer and activator of transcription 3 (STAT3) promoter methylation
      and expression in pituitary adenoma.
PG  - 72
LID - 10.1186/s12881-017-0434-3 [doi]
AB  - BACKGROUND: Pituitary adenoma (PA) is a benign brain tumor that can cause
      neurological, endocrinological and ophthalmological aberrations. Till now there
      is a need to identify factors that can influence the tumor invasiveness and
      recurrence. The aim of this study was to evaluate the associations between the
      signal transducer and activator of transcription 3 (STAT3) promoter methylation, 
      mRNA expression and the invasiveness or recurrence of PAs and patient clinical
      characteristics. METHODS: Study participants comprised of 102 subjects with a
      diagnosis of PA: 54 functioning and 48 non-functioning, 58 invasive and 30
      non-invasive PAs and 14 relapses. The bisulfite treatment of tumor DNA and
      methylation-specific polymerase chain reaction (MS-PCR) method was used to
      determine the STAT3 gene promoter methylation. For the STAT3 mRNA expression, the
      first-strand cDNA was produced from total RNA by using reverse transcriptase and 
      quantitative real-time PCR (qRT-PCR) was performed. RESULTS: In 10.78% (11/102)
      of PA tissues STAT3 gene promoter was methylated. A gender of male and patient
      group older than 60 years were significantly associated with reduced STAT3 mRNA
      expression (Mann-Whitney test, p = 0.025, p = 0.047, respectively). However, no
      more statistical differences were found between STAT3 promoter methylation, mRNA 
      expression and patient clinical characteristics or PA invasiveness or recurrence.
      CONCLUSIONS: Further investigations are needed to clarify the influence of STAT3 
      gene promoter methylation and mRNA expression changes in PAs.
FAU - Valiulyte, Indre
AU  - Valiulyte I
AUID- ORCID: http://orcid.org/0000-0002-0122-305X
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 2, LT-50009, Kaunas, Lithuania.
      [email protected]
FAU - Steponaitis, Giedrius
AU  - Steponaitis G
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 2, LT-50009, Kaunas, Lithuania.
FAU - Skiriute, Daina
AU  - Skiriute D
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 2, LT-50009, Kaunas, Lithuania.
FAU - Tamasauskas, Arimantas
AU  - Tamasauskas A
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 2, LT-50009, Kaunas, Lithuania.
FAU - Vaitkiene, Paulina
AU  - Vaitkiene P
AD  - Laboratory of Neurooncology and Genetics, Neuroscience Institute, Lithuanian
      University of Health Sciences, Eiveniu str. 2, LT-50009, Kaunas, Lithuania.
LA  - eng
PT  - Journal Article
DEP - 20170714
PL  - England
TA  - BMC Med Genet
JT  - BMC medical genetics
JID - 100968552
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (STAT3 Transcription Factor)
SB  - IM
MH  - DNA Methylation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness/genetics
MH  - Neoplasm Recurrence, Local/genetics
MH  - Pituitary Neoplasms/*genetics
MH  - *Promoter Regions, Genetic
MH  - RNA, Messenger/metabolism
MH  - RNA, Neoplasm/metabolism
MH  - Real-Time Polymerase Chain Reaction
MH  - STAT3 Transcription Factor/*genetics
PMC - PMC5513380
OTO - NOTNLM
OT  - DNA methylation
OT  - Invasiveness
OT  - Pituitary adenoma
OT  - Signal transducer and activator of transcription 3
OT  - mRNA expression
EDAT- 2017/07/16 06:00
MHDA- 2017/07/25 06:00
CRDT- 2017/07/16 06:00
PHST- 2017/03/24 [received]
PHST- 2017/07/06 [accepted]
AID - 10.1186/s12881-017-0434-3 [doi]
AID - 10.1186/s12881-017-0434-3 [pii]
PST - epublish
SO  - BMC Med Genet. 2017 Jul 14;18(1):72. doi: 10.1186/s12881-017-0434-3.